You are here

Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA235996-01A1
Agency Tracking Number: R41CA235996
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA18-575
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-09-01
Award End Date (Contract End Date): 2021-02-28
Small Business Information
Santa Barbara, CA 93101-2507
United States
DUNS: 078871379
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (513) 532-4084
Business Contact
Phone: (530) 913-2704
Research Institution
LOS ANGELES, CA 90089-0701
United States

 Nonprofit College or University

ABSTRACTBreast CancerBCis the leading cause of cancer death for woman in the USBreast cancer is treated by a combination of surgeryradiationand various types of chemo and targeted therapeutic strategiesApproximately half of patients who have positive sentinel lymph nodes at surgeryand as many asof patients who do noteventually present with metastatic diseaseOverof BC patients eventually have skeletal involvement making bone the single most prevalent site of metastasis in BCBioVinc has developed a novel bisphosphonate tagged PET imaging strategy which we have shown to more thoroughly image bone disease including earlier bone effects of disease than current PET probes of other diagnostic toolsIn this STTR Rapplication we proposend generationF BP PET imaging probes to provide breast cancer patientsa more sensitive measure of bone metastases prompting them to take advantage of new treatment strategies known to improve survival in this groupIt is our goal to show that these innovative BP PET probes can overcome some of the disadvantages of current imaging strategies for BC and provide earlier diagnosis of the bone metastasesOur innovative chemistry design offers rapid preparationwithin oneF half lifeof the proposed PET probesCold chemistry will be performed at the BioVinc laboratories by DrFrank Ebetino and the teamand then elaborated for radiochemistry requirements together with DrsKai Chen and Charles McKenna s group at USCAll radiochemistryincluding in situ cyclotron generation of the radioisotopeFas well as the in vivo animal studies and PET imaging will be performed under DrKai Chen s direction at the USC Molecular Imaging CenterWe will useF NaF probes as a control imaging agent in an orthotopic rodent model of breast cancer which reliably results in related bone metastases and compare them with our best novel probe for the detection of early changes in the bone due to diseaseThese proof of concept studies will position our research for rapid translational development in a subsequent Phase II STTR program PROJECT NARRATIVE Bone metastases is a serious potential side effect stemming from breast cancer and leads to serious skeletal related events including severe pain and fracturesThere is a serious unmet medical need for improved methods to promptly identify and manage therapy for this complicationA novel PET imaging probe to more accurately identify skeletal metastases will be developed and thereby reduce patient morbidity and mortality

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government